Roche Holding

Roche Holding is a holding company in the pharmaceutical industry. It is one of the leading manufacturers of biotech pharmaceuticals in the fields of oncology, virology, rheumatology and transplantology. The group includes the Swiss pharmaceutical company - F. Hoffmann-La Roche, Japanese Chugai, American Genentech and Foundation Medicine.
Roche Holding stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Roche Holding balance sheet

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Capitalization, CHF
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Roche Holding cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Roche Holding multipliers

Report period2017 2018 2019 2020 2021 2022
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Roche Holding profitability

Report period2017 2018 2019 2020 2021 2022
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Roche Holding assets
Roche Holding cash flows
Roche Holding dividends
0%

Roche Holding dividend policy

The company pays dividends once a year

Roche Holding shares

TickerNameTypeNominal valueISINPrice
RHHBY:USRoche HoldingDepositary receipt-US7711951043$31.32
Roche Holding news
30.03.2022
Roche's new immunotherapy Skyscraper 2 has failed to slow the progression of lung cancer. Roche will continue testing another drug against various types of cancer, tiragolumab.
Source: {source} pictogram reuters.com
Pictogram next
03.02.2022
Roche Holding's IFRS net income for 9 months of fiscal year 2021 was CHF14.935 billion, down 0.9% from CHF15.068 billion in the previous year. Revenues rose 7.7% to CHF62.801 billion versus CHF58.323 billion a year earlier.
Source: {source} pictogram roche.com
Pictogram next
31.01.2022
FDA has approved Roche's Vabysmo, a drug for the treatment of vision loss. Vabysmo is designed to treat neovascular NVMD and DME by neutralizing angiopoietin-2. A course of treatment for nVMD and DMO is given four times a month. The drug will go on sale in the U.S. in the coming weeks. The European Medicines Agency is also considering an application to regis...
Source: {source} pictogram roche.com
Pictogram next
27.12.2021
The Swiss regulator approved Ronapreve developed by Roche and Regeneron. The antibody-based drug is indicated for the treatment of COVID-19. At the time of the decision, no data were available on the efficacy of Ronapreve against the Omicron strain.
Source: {source} pictogram reuters.com
Pictogram next
All Roche Holding news
General information
Company nameRoche Holding
Tags#katie wood's choice, #pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business addressGrenzacherstrasse 124 Basel 4058 Switzerland
Mailing addressGrenzacherstrasse 124 Basel 4058 Switzerland
Websitewww.roche.com